FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joel Neutel

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Steven G Chrysant; F Wilford Germino; Joel M Neutel
Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Willa A Hsueh; Jen-Fue Maa; Ali Shojaee; Joel M Neutel
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
F Wilford Germino; Jen-Fue Maa; Joel M Neutel; Robert Dubiel; Kathleen J Chavanu
Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joel Neutel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Steven G Chrysant; F Wilford Germino; Joel M Neutel
Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2012;12(6):375-89.
2012: Willa A Hsueh; Jen-Fue Maa; Ali Shojaee; Joel M Neutel
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Current medical research and opinion 2012;28(11):1809-18.
2012: F Wilford Germino; Jen-Fue Maa; Joel M Neutel; Robert Dubiel; Kathleen J Chavanu
Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2012;12(5):325-33.
2012: Joel M Neutel; Richard Vinisko; Henry R Black; Bjorn Dahlöf; Holly Defeo; Ludwin Ley; Giusepe Mancia
Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.
Journal of clinical hypertension (Greenwich, Conn.) 2012;14(4):206-15.
2012: Arya M Sharma; Naitee Ting; George Bakris; Maureen Kobe; Thomas W Littlejohn; Joel M Neutel; Ludwin Ley
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
Clinical therapeutics 2012;34(3):537-51.
2011: Dean J Kereiakes; Joel M Neutel
Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
Drugs in R&D 2011;11(3):251-7.
2010: Henry Punzi; Joel M Neutel; Dean J Kereiakes; Ali Shojaee; William F Waverczak; Robert Dubiel; Jen-Fue Maa
Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
Therapeutic advances in cardiovascular disease 2010;4(4):209-21.
2010: Joel M Neutel; Dean J Kereiakes; William F Waverczak; Kathy A Stoakes; Jianbo Xu; Ali Shojaee
Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
Current medical research and opinion 2010;26(3):721-8.
2010: Joel M Neutel; Dean J Kereiakes
An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2010;10(5):289-303.
2010: Joel M Neutel
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
Current medical research and opinion 2010;26(1):213-22.
2010: Joel M Neutel; D H G Smith; A H Gradman
Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension.
Journal of human hypertension 2010;24(1):64-73.
2009: Joel M Neutel; Stanley S Franklin; Amitabha Bhaumik; Pablo Lapuerta; Suzanne Oparil
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Clinical and experimental hypertension (New York, N.Y. : 1993) 2009;31(7):572-84.
2009: Dean J Kereiakes; Joel M Neutel; Kathy A Stoakes; William F Waverczak; Jianbo Xu; Ali Shojaee; Robert Dubiel
The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.
Journal of clinical hypertension (Greenwich, Conn.) 2009;11(8):411-21.
2009: Robert Wolk; William B Smith; Joel M Neutel; John Rubino; Dawei Xuan; James Mancuso; James Gilbert; Milton L Pressler
Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension.
Hypertension 2009;53(6):1091-7.
2009: Steven G Chrysant; Joel M Neutel; Keith C Ferdinand
Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Journal of the National Medical Association 2009;101(4):300-7.
2009: Joel M Neutel
Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.
Postgraduate medicine 2009;121(2):40-8.
2009: Jay N Cohn; Daniel J Wilson; Joel M Neutel; Mark Houston; Myron H Weinberger; Richard Grimm; David H G Smith; William Sun
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
American journal of hypertension 2009;22(2):137-44.
2008: Joel M Neutel
Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
Current medical research and opinion 2008;24(8):2389-401.
2008: Elizabeth Ofili; Greg Cable; Joel M Neutel; Elijah Saunders
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.
Journal of women's health (2002) 2008;17(6):931-8.
2008: Joel M Neutel; S S Franklin; P Lapuerta; A Bhaumik; A Ptaszynska
A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
Journal of human hypertension 2008;22(4):266-74.
2008: Joel M Neutel; Lawrence I Gilderman
Hypertension control in the elderly.
Journal of clinical hypertension (Greenwich, Conn.) 2008;10(1 Suppl 1):33-9.
2008: William Cushman; Joel M Neutel; Elijah Saunders; George L Bakris; Keith C Ferdinand; Elizabeth Ofili; James R Sowers; Robert Madder; Michael A Weber
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
The American journal of geriatric cardiology 2008;17(1):27-36.
2007: Matthew R Weir; Joel M Neutel; Amitabha Bhaumik; Maria Elena De Obaldia; Pablo Lapuerta
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(12 Suppl 5):23-30.
2007: Keith C Norris; Joel M Neutel
Emerging insights in the first-step use of antihypertensive combination therapy.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(12 Suppl 5):5-14.
2007: Joel M Neutel; Domenic A Sica; Stanley S Franklin
Hypertension control: still not there-how to select the right add-on therapy to reach goal blood pressures.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(11):889-96.
2007: Philippe Gosse; Joel M Neutel; Helmut Schumacher; Yves Lacourcière; Bryn Williams; Giora Davidai
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.
Blood pressure monitoring 2007;12(3):141-7.
2007: Dean J Kereiakes; Joel M Neutel; Henry A Punzi; Jianbo Xu; Leslie J Lipka; Robert Dubiel
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2007;7(5):361-72.
2007: Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(1):45-8.
2007: Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(1):36-44.
2006: Joel M Neutel; Stanley S Franklin; Suzanne Oparil; Amitabha Bhaumik; Agata Ptaszynska; Pablo Lapuerta
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(12):850-7; quiz 858-9.
2006: William B White; Henry A Punzi; Debra Murwin; Stephen Koval; Giora Davidai; Joel M Neutel
Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(9):626-33.
2006: Franz H Messerli; George L Bakris; David Ferrera; Mark C Houston; Robert J Petrella; John M Flack; William Sun; EunMee Lee; Joel M Neutel
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(8):571-81; quiz 582-3.
2006: James R Sowers; Joel M Neutel; Elijah Saunders; George L Bakris; William Cushman; Keith C Ferdinand; Elizabeth Ofili; Michael A Weber
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(7):470-80.
2006: Joel M Neutel
The role of combination therapy in the management of hypertension.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(6):1469-73.
2006: Joel M Neutel; David H G Smith; Michael A Weber; Lesley Schofield; Das Purkayastha; Marjorie Gatlin
Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension.
The American journal of geriatric cardiology 2006;15(3):142-50.
2006: Elizabeth Ofili; Keith C Ferdinand; Elijah Saunders; Joel M Neutel; George L Bakris; William Cushman; James R Sowers; Michael A Weber
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
Journal of the National Medical Association 2006;98(4):618-26.
2006: Michael A Weber; William B White; Thomas D Giles; George L Bakris; Joel M Neutel; David H G Smith; Giora Davidai
An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(4):241-50; quiz 251-2.
2006: Joel M Neutel; D H G Smith; Tonous Silfani; Y Lee; Michael A Weber
Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.
Journal of human hypertension 2006;20(4):255-62.
2006: Yves Lacourcière; Joel M Neutel; Giora Davidai; Stephen Koval
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
American journal of hypertension 2006;19(1):104-12.
2006: William B White; Thomas Giles; George L Bakris; Joel M Neutel; Giora Davidai; Michael A Weber
Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting.
American heart journal 2006;151(1):176-84.
2005: Joel M Neutel; D Smith
Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.
The Journal of international medical research 2005;33(6):620-31.
2005: Yves Lacourcière; Joel M Neutel; Helmut Schumacher
Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Clinical therapeutics 2005;27(11):1795-805.
2005: Joel M Neutel; David H G Smith; Michael A Weber; Lesley Schofield; Das Purkayastha; Marjorie Gatlin
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(11):641-6; quiz 647-8.
2005: Joel M Neutel; Elijah Saunders; George L Bakris; William Cushman; Keith C Ferdinand; Elizabeth Ofili; James R Sowers; Michael A Weber
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(10):578-86.
2005: Joel M Neutel; F Wilford Germino; David Smith
Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2005;6(2):84-9.
2005: Joel M Neutel; Thomas W Littlejohn; Steven G Chrysant; Ashish Singh
Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension.
Hypertension research : official journal of the Japanese Society of Hypertension 2005;28(7):555-63.
2005: Joel M Neutel; Keith Rotenberg
Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in patients with hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(7):395-400; quiz 401-2.
2005: William B White; Michael A Weber; Giora Davidai; Joel M Neutel; George L Bakris; Thomas Giles
Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.
Blood pressure monitoring 2005;10(3):157-63.
2004: George L Bakris; Alan J Bank; David A Kass; Joel M Neutel; Richard A Preston; Suzanne Oparil
Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
American journal of hypertension 2004;17(12 Pt 2):23S-30S.
2004: Joel M Neutel
Combination therapy as initial treatment for hypertension.
Managed care (Langhorne, Pa.) 2004;13(7 Suppl):5-11; discussion 12-6.
2004: Domenic A Sica; Joel M Neutel; Michael A Weber; Neil Manowitz
The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2004;6(5):231-41.
2004: Joel M Neutel; David H G Smith; Michael A Weber; Antonia C Wang; Harvey N Masonson
Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.
Journal of clinical hypertension (Greenwich, Conn.) 2004;6(4):168-74.
2004: Jay N Cohn; Stevo Julius; Joel M Neutel; Michael Weber; Prasad Turlapaty; Yannan Shen; Victor M Dong; Alicia Batchelor; Weinong Guo; Lagast Hjalmar
Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial.
American journal of hypertension 2004;17(2):134-8.
2004: Thomas Unger; Gordon T McInnes; Joel M Neutel; Michael Böhm
The role of olmesartan medoxomil in the management of hypertension.
Drugs 2004;64(24):2731-9.
2004: Joel M Neutel; Michael A Weber; Stevo Julius; Jay N Cohn; Prasad Turlapaty; Yannan Shen; Weinong Guo; Alicia Batchelor; Lagast Hjalmar
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2004;4(5):335-41.
2004: Stevo Julius; Jay N Cohn; Joel M Neutel; Michael Weber; Prasad Turlapaty; Yannan Shen; Victor M Dong; Alicia Batchelor; Lagast Hjalmar
Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
Journal of clinical hypertension (Greenwich, Conn.) 2004;6(1):10-7.
2004: Joel M Neutel; David H G Smith; Michael A Weber
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.
American journal of hypertension 2004;17(1):37-42.
2003: Michael A Weber; George L Bakris; Joel M Neutel; Giora Davidai; Thomas D Giles
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
Journal of clinical hypertension (Greenwich, Conn.) 2003;5(5):322-9.
2003: Joel M Neutel; R E Kolloch; P F Plouin; Thomas W Meinicke; Helmut Schumacher
Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study.
Journal of human hypertension 2003;17(8):569-75.
2003: David H Smith; Joel M Neutel; Yves Lacourcière; Joan Kempthorne-Rawson
Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements.
Journal of hypertension 2003;21(7):1291-8.
2003: David H G Smith; Maarten-Jan M Cramer; Joel M Neutel; Rohan Hettiarachchi; Stephen Koval
Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies.
Blood pressure monitoring 2003;8(3):111-7.
2003: Joel M Neutel; David H G Smith
Improving patient compliance: a major goal in the management of hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2003;5(2):127-32.
2003: Stephen P Glasser; Joel M Neutel; Theophilus J Gana; Kenneth S Albert
Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension.
American journal of hypertension 2003;16(1):51-8.
2002: Joel M Neutel; William J Elliott; Joseph L Izzo; Chao L Chen; Harvey N Masonson
Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.
Journal of clinical hypertension (Greenwich, Conn.) 2002;4(5):325-31.
2002: Franz H Messerli; Matthew R Weir; Joel M Neutel
Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting.
American journal of hypertension 2002;15(6):550-6.
2002: Joel M Neutel; Christiane Klein; Thomas W Meinicke; Helmut Schumacher
Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications.
Blood pressure 2002;11(5):302-9.
2002: Joel M Neutel
The use of combination drug therapy in the treatment of hypertension.
Progress in cardiovascular nursing 2002;17(2):81-8.
2001: A Beltran; GE McVeigh; D Morgan; Stephen P Glasser; Joel M Neutel; M Weber; Stanley M Finkelstein; Jay N Cohn
Arterial compliance abnormalities in isolated systolic hypertension.
American journal of hypertension 2001;14(10):1007-11.
2001: Joel M Neutel
New blood pressure goals: the importance of combination therapy. Introduction.
American journal of hypertension 2001;14(5 Pt 2):1S-2S.
2001: Joel M Neutel
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
The American journal of cardiology 2001;87(8A):37C-43C.
2001: Joel M Neutel; David H G Smith; Michael A Weber
Low-dose combination therapy: an important first-line treatment in the management of hypertension.
American journal of hypertension 2001;14(3):286-92.
2001: Joel M Neutel
Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker--telmisartan.
Blood pressure. Supplement 2001;1():27-32.
2000: Joel M Neutel
Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other antihypertensive drugs.
Blood pressure monitoring 2000;5 Suppl 1():S35-40.
1999: Joel M Neutel; David H G Smith
Hypertension control: multifactorial contributions.
American journal of hypertension 1999;12(12 Pt 1-2):164S-169S.
1999: Joel M Neutel; David H G Smith; Michael A Weber
Is high blood pressure a late manifestation of the hypertension syndrome?
American journal of hypertension 1999;12(12 Pt 3):215S-223S.
1999: Joel M Neutel
Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management.
American journal of hypertension 1999;12(8 Pt 2):73S-79S.
1999: Joel M Neutel
Safety and efficacy of angiotensin II receptor antagonists.
The American journal of cardiology 1999;84(2A):13K-17K.
1999: Joel M Neutel; W H Frishman; S Oparil; V Papademitriou; G Guthrie
Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.
American journal of therapeutics 1999;6(3):161-6.
1999: Joel M Neutel; D H Smith; P A Reilly
The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension.
International journal of clinical practice 1999;53(3):175-8.
1999: Joel M Neutel; David H G Smith; M A Weber
What are the approaches for evaluating antihypertensive treatment by 24 h ambulatory blood pressure monitoring?
Blood pressure monitoring 1999;4 Suppl 2():S23-8.
1998: Joel M Neutel; David H G Smith
Hypertension: where have we gone wrong and how can we fix it?
American journal of hypertension 1998;11(10):150S-157S.
1997: Joel M Neutel; David H G Smith; W H Frishman
Optimization of antihypertensive therapy with a novel, extended-release formulation of diltiazem: results of a practice-based clinical study.
Clinical therapeutics 1997;19(6):1379-93.
1997: Joel M Neutel; M Weber; James L Pool; D Smith; S Fitzsimmons; Yann-Tong Chiang; M Gatlin
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours.
Clinical therapeutics 1997;19(3):447-58; discussion 367-8.
1997: Joel M Neutel; Darrell R. Abernethy; M Moser; R W Gifford; W H Frishman
Discussion: recent data on the safety and efficacy of newer therapies in the management of hypertension.
American journal of hypertension 1997;10(3):24S-26S.